



**Intellectual Property  
Technology Law**

1414 Raleigh Road, Suite 201  
Chapel Hill, NC 27517

P.O. Box 14329  
Research Triangle Park, NC 27709

Phone: (919) 419-9350  
Fax: (919) 419-9354  
[Info@iptl.com](mailto:Info@iptl.com) • [www.iptl.com](http://www.iptl.com)

# Fax

---

<b>To:</b>	U.S. Patent and Trademark Office Examiner U. Winkler	<b>From:</b>	Marianne Fuierer
<b>Fax:</b>	703-746-3162	<b>Date:</b>	March 19, 2003
<b>Phone:</b>		<b>Pages:</b>	(including this page) 3
<b>Re:</b>	U.S. Patent Application no. 09/934,060	<b>File:</b>	4115-144 CIP

---

Original Document to: ☐ Follow via Regular Mail ☐ Follow via Express Mail ☒ Not to be sent (unless requested)

---

## Comments

Please deliver to Examiner Winkler in Group 1600.

Thank you

Marianne Fuierer

**CONFIDENTIALITY NOTE: THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL AT THE ADDRESS SET OUT ABOVE.**

Sent by


#14  
H. Winkler  
3/25/03

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>In re United States Patent Application of:</b>	)	<b>Docket No.:</b>	<b>4115-144 CIP</b>
<b>Applicant:</b>	)	<b>Examiner:</b>	<b>U. Winkler PhD</b>
<b>Serial No.:</b>	)	<b>Group Art Unit:</b>	<b>1648</b>
<b>Date Filed:</b>	)	<b>Confirmation No.:</b>	<b>8085</b>
<b>Title:</b>	)	<b>Customer No.:</b>	<b>23448</b>
<b>VIRUS COAT PROTEIN/RECEPTOR CHIMERAS AND METHODS OF USE</b>	)		

**FACSIMILE TRANSMISSION CERTIFICATE****Fax No.: 703-746-3162**

I hereby certify that this document is being filed in the United States Patent and Trademark Office, via facsimile transmission to Commissioner for Patents, Washington, D.C. 20231, on March 19, 2003, to United States Patent and Trademark Office facsimile transmission number:



Marianne Fuierer

March 19, 2003

Date

**RESPONSE TO EXAMINER'S REQUEST IN U.S. PATENT APPLICATION NO.  
09/934,060**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to Examiner Winkler's request for defining the example chimeric polypeptides recited in the above-identified application, applicants provide the following list of polypeptides and the amino acid sequences of the chimeric polypeptide.

1. A truncated single chain chimeric polypeptide (TsSC) (SEQ ID NO. 13) comprising a viral coat (BaL gp120; SEQ ID NO. 28) - spacer - a viral receptor (CD4D1D2; SEQ ID No. 26), (see page 26 of specification);

2. A full length single chain chimeric polypeptide (FLSC) (SEQ ID NO. 2) comprising a viral coat ( $\Delta$ C1 $\Delta$ C5 $\Delta$ V1V2 gp120; SEQ ID NO. 24) - spacer - a viral receptor (CD4D1D2; SEQ ID NO. 26), (see page 21 of specification);

3. A chimeric polypeptide having a mutation at the c-terminal of gp120 (FLSC-RT; SEQ ID NO. 4) comprising a viral coat (mutated gp120; SEQ ID NO. 30) - spacer - a viral receptor (CD4D1D2; SEQ ID NO. 26), (see page 21 of specification); and

4. A chimeric polypeptide having a mutation at the c-terminal of gp120 (FLSC-RT CD4M9; SEQ ID NO. 6) comprising a viral coat (mutated gp120; SEQ ID NO. 30) - spacer - a peptide that mimics a viral receptor (CD4M9; SEQ ID NO. 20), (see page 22 of specification).

The amino acid spacer used in each of the above chimeric polypeptides is SEQ ID NO. 11, (see page 51 of specification).

The nucleotide sequences relating to each of the above-identified chimeric polypeptides are as follows:

1. (TsSC) (SEQ ID NO. 12) which comprises SEQ ID NOs. 27 (viral coat) and 25 (viral receptor), (see page 26 of specification);
2. (FLSC) (SEQ ID NO. 1) which comprises SEQ ID NOs. 23 (viral coat) and 25 (viral receptor), (see page 26 of specification);
3. (FLSC-RT) (SEQ ID NO. 3) which comprises SEQ ID NOs. 29 (viral coat) and 25 (viral receptor), (see page 26 of specification); and
4. (FLSC-RT CD4M9) (SEQ ID NO. 5) which comprises SEQ ID NOs. 29 (viral coat) and 19 (viral receptor), (see page 26 of specification).

Applicants believe this information will help Examiner Winkler in discerning the chimeric polypeptides and related amino acid sequences and nucleotide sequences.

If further information is required, please contact the undersigned attorney at 919-419-9350.

Respectfully submitted,



Marianne Fuierer  
Reg. No. 39,983  
Attorney for Applicants

INTELLECTUAL PROPERTY/  
TECHNOLOGY LAW  
Telephone: (919) 419-9350  
Fax: (919) 419-9354  
Attorney Ref: 4115-144 CIP